Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Charlton RA, Jordan S, Pierini A et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG 122(7), 1010–1020 (2015).
  Medline CASGoogle Scholar
• 2 Andrade SE, Raebel MA, Brown J et al. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol. 198(2), 194–195 (2008).
  MedlineGoogle Scholar
• 3 Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharmacol. 51(2), 264–270 (2011).
  MedlineGoogle Scholar
• 4 Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth defects Res. A Clin. Mol. Teratol. 88(3), 159–170 (2010).
  Medline CASGoogle Scholar
• 5 Grigoriadis S, VonderPorten EH, Mamisashvili L et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J. Clin. Psychiatry. 74(4), e293–e308 (2013).
  Medline CASGoogle Scholar
• 6 Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust. N. Z. J. Psychiatry 47(11), 1002–1012 (2013).
  MedlineGoogle Scholar
• 7 Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. J. Am. Heart Assoc. 4(5), e001681 (2015).
  MedlineGoogle Scholar
• 8 Daud A, Bergman J, Kerstjens-Frederikse W, Groen H, Wilffert B. The risk of congenital heart anomalies following prenatal exposure to serotonin reuptake inhibitors – is pharmacogenetics the key? Int. J. Mol. Sci. 17(8), E1333 (2016).
  MedlineGoogle Scholar
• 9 Swen JJ, Wilting I, de Goede AL et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83(5), 781–787 (2008).
  Medline CASGoogle Scholar
• 10 Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89(5), 662–673 (2011).
  Medline CASGoogle Scholar
• 11 Daud AN, Bergman JE, Bakker MK et al. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics 15(7), 1029–1041 (2014).
  CASGoogle Scholar
• 12 Fabbri C, Minarini A, Niitsu T, Serretti A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin. Drug Metab. Toxicol. 10(8), 1093–1118 (2014).
  Medline CASGoogle Scholar
• 13 Kroeze Y, Zhou H, Homberg JR. The genetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 136(3), 375–400 (2012).
  Medline CASGoogle Scholar
• 14 Wilkie MJ, Smith G, Day RK et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 9(1), 61–70 (2009).
  Medline CASGoogle Scholar
• 15 Hassanzadeh J, Moradzadeh R, Rajaee Fard A, Tahmasebi S, Golmohammadi P. A comparison of case–control and case–only designs to investigate gene–environment interactions using breast cancer data. Iran. J. Med. Sci. 37(2), 112–118 (2012).
  MedlineGoogle Scholar
• 16 Li D, Conti DV. Detecting gene–environment interactions using a combined case–only and case–control approach. Am. J. Epidemiol. 169(4), 497–504 (2009).
  MedlineGoogle Scholar
• 17 Albert PS, Ratnasinghe D, Tangrea J, Wacholder S. Limitations of the case-only design for identifying gene–environment interactions. Am. J. Epidemiol. 154(8), 687–693 (2001).
  Medline CASGoogle Scholar
• 18 European Surveillance of Congenital Anomalies (EUROCAT). Subgroups of congenital anomalies (Version 2012). www.eurocat-network.eu/content/EUROCAT-Guide-1.4-Section-3.3.pdf.
  Google Scholar
• 19 Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug–drug interactions involving P-glycoprotein. CNS Drugs 26(11), 959–973 (2012).
  Medline CASGoogle Scholar
• 20 Hodges LM, Markova SM, Chinn LW et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics 21(3), 152–161 (2011).
  Medline CASGoogle Scholar
• 21 Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod. Toxicol. 32(4), 484–489 (2011).
  Medline CASGoogle Scholar
• 22 The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Allele nomenclature for Cytochrome P450 enzymes. www.cypalleles.ki.se/.
  Google Scholar
• 23 Gex-Fabry M, Eap CB, Oneda B et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit. 30(4), 474–482 (2008).
  Medline CASGoogle Scholar
• 24 Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr. Genet. 19(6), 281–291 (2009).
  MedlineGoogle Scholar
• 25 Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation, interpretationand analysis. Nucleic Acids Res. 40, D1308–D1312 (2012).
  Medline CASGoogle Scholar
• 26 Caudle KE, Dunnenberger HM, Freimuth RR et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet. Med. 19, 215–223 (2016).
  MedlineGoogle Scholar
• 27 Swen JJ, Guchelaar H-JJ, Baak-Pablo RF, Assendelft WJJ, Wessels JAM. Genetic risk factors for Type 2 diabetes mellitus and response to sulfonylurea treatment. Pharmacogenet. Genomics 21(8), 461–468 (2011).
  Medline CASGoogle Scholar
• 28 Nelveg-Kristensen KE, Madsen MB, Torp-Pedersen C et al. Pharmacogenetic risk stratification in angiotensin-converting enzyme inhibitor-treated patients with congestive heart failure: a retrospective cohort study. PLoS ONE. 10(12), e0144195 (2015).
  MedlineGoogle Scholar
• 29 Meigs JB, Shrader P, Sullivan LM et al. Genotype score in addition to common risk factors for prediction of Type 2 diabetes. N. Engl. J. Med. 359(21), 2208–2219 (2008).
  Medline CASGoogle Scholar
• 30 NCIB. dbSNP short genetic variations. www.ncbi.nlm.nih.gov/SNP/.
  Google Scholar
• 31 Ensembl. www.ensembl.org/index.html.
  Google Scholar
• 32 Hitzl M, Schaeffeler E, Hocher B et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics. 14(5), 309–318 (2004).
  Medline CASGoogle Scholar
• 33 Molsa M, Heikkinen T, Hakkola J et al. Functional role of P-glycoprotein in the human blood–placental barrier. Clin. Pharmacol. Ther. 78(2), 123–131 (2005).
  MedlineGoogle Scholar
• 34 Rahi M, Heikkinen T, Härtter S et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J. Psychopharmacol. 21(7), 751–756 (2007).
  Medline CASGoogle Scholar
• 35 Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GDV, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem. Pharmacol. 79(6), 921–925 (2010).
  Medline CASGoogle Scholar
• 36 Noordam R, Aarts N, Hofman A, van Schaik RHN, Stricker BH, Visser LE. Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. J. Clin. Psychopharmacol. 33(4), 546–550 (2013).
  Medline CASGoogle Scholar
• 37 Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(2), 398–404 (2008).
  Medline CASGoogle Scholar
• 38 Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol. Res. 58(5–6), 344–347 (2008).
  Medline CASGoogle Scholar
• 39 Lin KM, Chiu YF, Tsai IJ et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet. Genomics 21(4), 163–170 (2011).
  Medline CASGoogle Scholar
• 40 Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl. Psychiatry 2, e198 (2012).
  Medline CASGoogle Scholar
• 41 Fukui N, Suzuki Y, Sawamura K et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther. Drug Monit. 29(2), 185–189 (2007).
  Medline CASGoogle Scholar
• 42 Obermann-Borst SA, Isaacs A, Younes Z et al. General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. Am. J. Obstet. Gynecol. 204(3), 236.e1–8 (2011).
  Google Scholar
• 43 Bliek BJB, van Schaik RHN, van der Heiden IP et al. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am. J. Med. Genet. A 149A(10), 2088–2092 (2009).
  Medline CASGoogle Scholar
• 44 Wang C, Zhou K, Xie L et al. Maternal medication use, fetal 3435 C>T polymorphism of the ABCB1 gene, and risk of isolated septal defects in a Han Chinese population. Pediatr. Cardiol. 35, 1132–1141 (2014).
  MedlineGoogle Scholar
• 45 Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53, 186–195 (2006).
  Medline CASGoogle Scholar
• 46 Lee SH, Choi TK, Lee E et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 62(3), 198–206 (2010).
  Medline CASGoogle Scholar
• 47 Hu X-Z, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783–792 (2007).
  Medline CASGoogle Scholar
• 48 Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61(11), 1163–1169 (2004).
  Medline CASGoogle Scholar
• 49 Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet. Test. Mol. Biomarkers 18(1), 20–31 (2014).
  Medline CASGoogle Scholar
• 50 Bottalico B, Pilka R, Larsson I, Casslen B, Marsal K, Hansson SR. Plasma membrane and vesicular monoamine transporters in normal endometrium and early pregnancy decidua. Mol. Hum. Reprod. 9(7), 389–394 (2003).
  Medline CASGoogle Scholar
• 51 Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 6(5), 351–356 (2006).
  Medline CASGoogle Scholar
• 52 Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 197, 1–7 (2011).
  Medline CASGoogle Scholar
• 53 Hobbs CA, Cleves MA, Karim MA, Zhao W, MacLeod SL. Maternal folate-related gene environment interactions and congenital heart defects. Obstet. Gynecol. 116, 316–322 (2010).
  MedlineGoogle Scholar
• 54 Hobbs CA, Cleves MA, Macleod SL et al. Conotruncal heart defects and common variants in maternal and fetal genes in folate, homocysteine, and transsulfuration pathways. Birth Defects Res. A Clin. Mol. Teratol. 100(2), 116–126 (2014).
  Medline CASGoogle Scholar
• 55 Tang X, Nick TG, Cleves MA et al. Maternal obesity and tobacco use modify the impact of genetic variants on the occurrence of conotruncal heart defects. PLoS ONE. 9(10), e108903 (2014).
  MedlineGoogle Scholar
• 56 Tang X, Hobbs CA, Cleves MA et al. Genetic variation affects congenital heart defect susceptibility in offspring exposed to maternal tobacco use. Birth Defects Res. A Clin. Mol. Teratol. 103(10), 834–842 (2015).
  Medline CASGoogle Scholar
• 57 Wang LY, Lee WC. Population stratification bias in the case-only study for gene–environment interactions. Am. J. Epidemiol. 168(2), 197–201 (2008).
  MedlineGoogle Scholar
• 58 Haas DM, D'Alton M. Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug? Obstet. Gynecol. 120(5), 1176–1179 (2012).
  Medline CASGoogle Scholar
• 59 Haas DM. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future. Obstet. Gynecol. Surv. 68(9), 650–654 (2013).
  MedlineGoogle Scholar
• 60 Quinney SK, Patil AS, Flockhart DA. Is personalized medicine achievable in obstetrics? Semin. Perinatol. 38(8), 534–540 (2014).
  MedlineGoogle Scholar
• 61 Dorfman EH, Cheng EY, Hebert MF, Thummel KE, Burke W. Prenatal pharmacogenomics: a promising area for research. Pharmacogenomics J. 16(4), 303–304 (2016).
  Medline CASGoogle Scholar
• 62 Li M, Li J, Wei C et al. A three-way interaction among maternal and fetal variants contributing to congenital heart defects. Ann. Hum. Genet. 80(1), 20–31 (2016).
  Medline CASGoogle Scholar